Cassava sciences reports second quarter financial results for 2022, mid-year corporate update and interim analysis of open-label study

Austin, texas, aug. 03, 2022 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a clinical-stage biotechnology company focused on alzheimer's disease, today announced financial results for the second quarter ended june 30, 2022, a mid-year corporate update, and interim clinical results of an open-label study with simufilam. simufilam is cassava sciences' lead drug candidate for the proposed treatment of alzheimer's disease. savadx is cassava sciences' investigational diagnostic candidate to detect alzheimer's disease from a simple blood draw.
SAVA Ratings Summary
SAVA Quant Ranking